ICER's Ambitious 2018 Review Agenda Takes On Groundbreaking Treatments
Institute for Clinical and Economic Review plans to evaluate the cost effectiveness of gene therapy, CAR-T drugs and tissue-agnostic cancer drugs, among other treatments, in 2018.
You may also be interested in...
Proposed list of topics for review in 2019 by the Institute for Clinical and Economic Review includes a total of 15 drugs but that could change as the year goes on.
Luxturna, a one-time treatment for a rare inherited form of blindness, would not be cost-effective at the $1m price level that has been suggested as a possibility, based on ICER's thresholds. But the small patient population would keep it from triggering ICER's US budget spending threshold.
The Centers for Medicare and Medicaid Services will only pay for Kymriah if patients respond after one month. Novartis also pursuing similar contracts with private payers.